Moleculin Biotech, Inc. (NASDAQ:MBRX) Sees Large Growth in Short Interest

Moleculin Biotech, Inc. (NASDAQ:MBRX) was the recipient of a large increase in short interest in the month of February. As of February 15th, there was short interest totalling 2,200,000 shares, an increase of 1,169.5% from the January 31st total of 173,300 shares. Approximately 54.6% of the shares of the company are sold short. Based on an average daily volume of 5,000,000 shares, the short-interest ratio is presently 0.4 days.

Moleculin Biotech Stock Up 1.6 %

Moleculin Biotech stock opened at $1.29 on Friday. Moleculin Biotech has a 12 month low of $0.40 and a 12 month high of $10.35. The company has a fifty day moving average price of $1.54 and a two-hundred day moving average price of $2.16.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Maxim Group downgraded shares of Moleculin Biotech from a “buy” rating to a “hold” rating in a report on Wednesday, February 12th. StockNews.com began coverage on shares of Moleculin Biotech in a report on Tuesday. They issued a “sell” rating on the stock.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.